It's not impossible to tell, we will know in 3-6 months. The clinical trial updates will need to released whether they are further positive update or poor. CHECKvacc was discontinue as it's now covered by VAXINIA, it's too expensive to commence Ph3 clinical trial for HER-Vaxx and why wouldn't IMU divert the fund and resource to the 3 IP with FDA IND, Fast Track designation and path to registrational clinical trial instead of PD1-Vaxx which will be more expensive as it's in Ph2 clinical trial????
IMU Price at posting:
3.9¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)